HOXA5 and p53 cooperate to suppress lung cancer cell invasion and serve as good prognostic factors in non-small cell lung cancer.

Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell (1997) 16.79

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68

Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 4.83

Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 4.69

Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One (2013) 4.31

Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature (2000) 3.78

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 3.06

Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood (2007) 2.83

Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A (1995) 2.76

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.31

Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 1.77

MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer (2012) 1.61

Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol (1997) 1.57

A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene (2009) 1.50

The HOX homeodomain proteins block CBP histone acetyltransferase activity. Mol Cell Biol (2001) 1.24

Disordered expression of HOX genes in human non-small cell lung cancer. Oncol Rep (2006) 1.19

HOXA5-twist interaction alters p53 homeostasis in breast cancer cells. J Biol Chem (2004) 1.19

Impact of the loss of Hoxa5 function on lung alveogenesis. Am J Pathol (2006) 1.12

Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther (2007) 1.02

Partial functional redundancy between Hoxa5 and Hoxb5 paralog genes during lung morphogenesis. Am J Physiol Lung Cell Mol Physiol (2013) 0.94

Stromal Hoxa5 function controls the growth and differentiation of mammary alveolar epithelium. Dev Dyn (2006) 0.94

p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res (1998) 0.93

Expression pattern of a homeotic gene, HOXA5, in normal breast and in breast tumors. Cell Oncol (2006) 0.91

Unique spatial and cellular expression patterns of Hoxa5, Hoxb4, and Hoxb6 proteins in normal developing murine lung are modified in pulmonary hypoplasia. Birth Defects Res A Clin Mol Teratol (2008) 0.90

Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma. Pathol Int (2010) 0.90

Influence of Hoxa5 on p53 tumorigenic outcome in mice. Am J Pathol (2009) 0.89

Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells. Br J Cancer (2014) 0.88

Homeobox gene expression profile indicates HOXA5 as a candidate prognostic marker in oral squamous cell carcinoma. Int J Oncol (2011) 0.87

Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features. Mol Carcinog (2009) 0.85

Nuclear and cytoplasmic p53 suppress cell invasion by inhibiting respiratory complex-I activity via Bcl-2 family proteins. Oncotarget (2014) 0.84

The loss of Hoxa5 function promotes Notch-dependent goblet cell metaplasia in lung airways. Biol Open (2012) 0.84

DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach. BMC Gastroenterol (2014) 0.82

miR-1271 promotes non-small-cell lung cancer cell proliferation and invasion via targeting HOXA5. Biochem Biophys Res Commun (2015) 0.82

Respiratory adaptations to lung morphological defects in adult mice lacking Hoxa5 gene function. Pediatr Res (2004) 0.81

Clinical implications of p53 mutations in lung cancer. Methods Mol Med (2003) 0.81

HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma. PLoS One (2015) 0.81

p53 controls hPar1 function and expression. Oncogene (2008) 0.79

Diagnostic surgical pathology in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 0.79

Increased DNA methylation in the HoxA5 promoter region correlates with decreased expression of the gene during tumor promotion. Mol Carcinog (2004) 0.77

Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition. Oncotarget (2016) 0.78